Assessing the use of activated protein c in the treatment of severe sepsis.

被引：96

作者：

Siegel, JP ^{[1
]}

机构：

[1] Ctr Biol Evaluat & Res, Rockville, MD 20852 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2002年 / 347卷 / 13期

关键词：

D O I：

10.1056/NEJMsb021512

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1030 / 1034

页数：6

共 6 条

[1]

*ANT ADV COMM, 2001, FDA BRIEF DOC DROTR

[2] Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].

Bernard, GR ;

Vincent, JL ;

Laterre, P ;

LaRosa, SP ;

Dhainaut, JF ;

Lopez-Rodriguez, A ;

Steingrub, JS ;

Garber, GE ;

Helterbrand, JD ;

Ely, EW ;

Fisher, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709

[3]

*FDA, 2001, ANT DRUGS ADV COMM M

[4]

*FDA, IN PRESS FDA CLIN RE

[5] APACHE-II - A SEVERITY OF DISEASE CLASSIFICATION-SYSTEM [J].

KNAUS, WA ;

DRAPER, EA ;

WAGNER, DP ;

ZIMMERMAN, JE .

CRITICAL CARE MEDICINE, 1985, 13 (10) :818-829

[6] Risks and benefits of activated protein C treatment for severe sepsis. [J].

Warren, HS ;

Suffredini, AF ;

Eichacker, PQ ;

Munford, RS .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :1027-1030

← 1 →